Organon Has Expanded Its Agreement With Eli Lilly To Become The Sole Distributor And Promoter Of The Migraine Medicine Emgality (Galcanezumab) In Additional Markets, Total Consideration To Be Paid To Lilly Includes An Upfront Payment Of $22.5M As Well As Sales-based Milestone Payments
Author: Benzinga Newsdesk | August 20, 2024 07:34am